Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimer’s Disease
Mar Cuadrado‐Tejedor(University of Copenhagen), Ana García‐Osta(Navarre Institute of Health Research)
Cited by 46
Related Papers
Phenylbutyrate Ameliorates Cognitive Deficit and Reduces Tau Pathology in an Alzheimer's Disease Mouse Model
|Neuropsychopharmacology|2009|413
Sildenafil restores cognitive function without affecting β-amyloid burden in a mouse model of Alzheimer's disease
|British Journal of Pharmacology|2011|210
Enhanced Expression of the Voltage-Dependent Anion Channel 1 (VDAC1) in Alzheimer's Disease Transgenic Mice: An Insight into the Pathogenic Effects of Amyloid-β
|Journal of Alzheimer s Disease|2011|137
A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer’s Disease Mice
|Neuropsychopharmacology|2016|104
MuSK Expressed in the Brain Mediates Cholinergic Responses, Synaptic Plasticity, and Memory Formation
|Journal of Neuroscience|2006|94